WHO Seeks Key Data to Guide 2025 COVID-19 Vaccines

Industry Insights from Next Move Strategy Consulting

As SARS-CoV-2 variants continue to evolve, the World Health Organization's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has issued a pivotal statement guiding the generation of critical data to shape December 2025 vaccine antigen deliberations. This update emphasizes the need for comprehensive genetic, antigenic, and effectiveness data on emerging variants, ensuring vaccines remain aligned with global health threats and manufacturing timelines.

A Strategic Call for Evidence-Driven Vaccine Evolution

The TAG-CO-VAC's ongoing surveillance of SARS-CoV-2's genetic and antigenic changes, alongside immune responses and vaccine performance, underscores the dynamic nature of COVID-19 protection. Scheduled for December 2025, the next meeting will balance cutting-edge epidemiological, immunological, and virological insights with the kinetics of vaccine-induced immunity and production lead times. This statement refines earlier guidance from March 2025, focusing on data that directly informs antigen composition updates for authorized vaccines.

By prioritizing variant-specific analyses, the advisory aims to equip manufacturers and regulators with actionable intelligence, fostering vaccines that sustain broad protection against infection, symptomatic disease, and severe outcomes.

Essential Data Priorities at a Glance

The statement highlights targeted data requirements to illuminate SARS-CoV-2's trajectory:

• Genetic evolution tracking, centered on Variants of Interest (VOI) and Variants Under Monitoring (VUM) listed on the WHO website.

• Antigenic profiling of variants like XBB.1.5, JN.1, KP.2, XEC, LP.8.1, NB.1.8.1, XFG, and emerging strains including BA.3.2, using animal antisera in one-way and two-way neutralization tests.

• Immunogenicity assessments measuring neutralization breadth and durability, from non-naïve animal models and human pre/post-vaccination sera against representative viruses.

• Vaccine effectiveness (VE) metrics, including relative estimates during JN.1 descendant circulation, stratified by time since vaccination, age groups, and outcomes like infection or severe disease defined by specific criteria such as oxygen use.

• Manufacturer-submitted data on immune response breadth from current vaccines and candidates, plus observational efficacy against key variants.

Implications for the Vaccines Market: Next Move Strategy Consulting’s View

This WHO directive underscores the critical need for variant-specific data in the global vaccines market, where adaptability to emerging SARS-CoV-2 variants is essential. By prioritizing data on monovalent formulations like LP.8.1, JN.1, KP.2, and XBB.1.5, the TAG-CO-VAC creates opportunities for manufacturers to demonstrate robust variant coverage, potentially strengthening their competitive positioning. The emphasis on detailed vaccine effectiveness (VE) data, particularly for severe outcomes and across age groups, could inform regulatory and payer evaluations, highlighting vaccines with superior performance. The focus on broad immunogenicity and durability encourages manufacturers to explore diverse vaccine candidates, mitigating risks from evolving variants. This evidence-driven approach supports timely updates to vaccine compositions, fostering sustained market relevance.

Fostering Global Preparedness Through Collaboration

The TAG-CO-VAC's framework not only refines decision-making but also promotes interoperability across research ecosystems, urging comparable immunogenicity benchmarks and variant-specific VE across platforms. With references to prior statements dating back to 2022, this iterative approach reinforces WHO's role in harmonizing global vaccine strategies.

As SARS-CoV-2 adaptation persists, the December 2025 deliberations promise to fortify defenses, ensuring equitable and effective immunization worldwide.

Source: WHO

Prepared by: Next Move Strategy Consulting